First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate

Br J Haematol. 2014 Oct;167(1):139-41. doi: 10.1111/bjh.12937. Epub 2014 May 10.

Authors

Ahmet Emre Eskazan¹, Mesut Ayer, Bulent Kantarcioglu, Deniz Arica, Naciye Demirel, Demet Aydin, Fevzi Firat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren Aydin, Zafer Baslar, Yildiz Aydin, Nukhet Tuzuner, Ugur Ozbek, Teoman Soysal

Affiliation

¹ Division of Haematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.

PMID: 24815307
DOI: 10.1111/bjh.12937

No abstract available

Keywords: chronic myeloid leukaemia; efficacy; generic; imatinib mesylate.

Publication types

Letter

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Benzamides / therapeutic use*
Humans
Imatinib Mesylate
Leukemia, Myeloid, Chronic-Phase / drug therapy*
Piperazines / therapeutic use*
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Pyrimidines / therapeutic use*
Treatment Outcome

Substances

Antineoplastic Agents
Benzamides
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate